You are here

  • Home
  • Archive
  • Volume 39, Issue 3
  • Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings: authors’ response

Article Text

Article menu
Download PDFPDF
Letters to the editor
Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings: authors’ response
  1. Samuel Shapiro, MB, FRCP(E)
  1. Visiting Professor of Epidemiology, Department of Epidemiology, University of Cape Town, Cape Town, South Africa; samshap@mweb.co.za
  1. Richard D T Farmer, MB, PhD
  1. Emeritus Professor of Epidemiology, Department of Epidemiology, University of Surrey, Guildford, UK; richard.farmer1@btopenworld.com
  1. John C Stevenson, FRCB. MFSEM
  1. Consultant Physician and Reader in Metabolic Medicine, National Heart and Lung Institute, Imperial College London, Royal Brompton Hospital, London, UK; j.stevenson@imperial.ac.uk
  1. Henry G Burger, MD, FRACP
  1. Emeritus Director, Prince Henry's Institute of Medical Research, Monash Medical Centre, Clayton, Victoria, Australia; Consultant Endocrinologist, Jean Hailes Medical Centre for Women's Health, Clayton, Victoria, Australia; henry.burger@princehenrys.org
  1. Alfred O Mueck, MD, PhD
  1. Professor of Clinical Pharmacology and Endocrinology, Department of Endocrinology, University Women's Hospital, Tubingen, Germany; anne.gompel@cch.aphp.fr
  1. Anne Gompel
  1. Professor of Gynaecology, Gynaecological Endocrinology Unit, Paris Descartes University, APHP, Port-Royal Hospital, Paris, France; anne.gompel@htd.aphp.fr

https://doi.org/10.1136/jfprhc-2013-100673

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Drs Chlebowski, Nikolaenko and Anderson for their comments.1

    We have previously reviewed2 the article published by Chlebowski and his colleagues in the New England Journal of Medicine,3 and the claim that it documented that “mammography use was similar in the hormone-therapy and placebo groups … before and after the intervention [i.e. the Women's Health Initiative (WHI) clinical trial]” is incorrect. Only the percentages of breast cancer that were detected by mammography were documented.

    In a subsequent article Chlebowski et al. 4 stated that “mammography frequency was comparable in the two randomization groups during the original trial period … (annualized percentage, 80% for hormone vs 80% for placebo). In the reconsenting population [i.e. women who consented for long-term follow-up after the protocol-specified trial period ended] … the percentages of women with one or more mammograms were also comparable … (86% for hormone vs 86% placebo [sic])”. However, the annual numbers, or the rates, of mammography among the women who stopped their treatments, either during the trial or thereafter, …

    View Full Text

    Footnotes

    • Competing interests Samuel Shapiro, John Stevenson, Henry Burger, Alfred Mueck and Anne Gompel presently consult, and in the past have consulted, with manufacturers of products discussed in this article. Richard Farmer has consulted with manufacturers in the past.

    • Provenance and peer review Commissioned; internally peer reviewed.